- German Social Democrat-led coalition expected to liberalize medical cannabis market
- Analysts predict over one million medical cannabis patients in Germany by 2024, market estimated to reach $8.9 billion by 2028
- RYAH entered German market via observational study with Four 20 Pharma GmbH
- RYAH provides IoT product ecosystem of volume-control devices, medicine-carrying components, mobile applications
- RYAH ecosystem offers reliable way for researchers and clinicians to develop well-controlled research environments
Germany’s recent 2021 election is expected to result in a new political environment via a coalition containing cannabis-positive political factions that aim to liberalize the country’s plant-based medicine market (https://ibn.fm/t1Zgg). RYAH Group (CSE: RYAH), the leader in volume-control technology for plant-based medicine, is already on track to penetrate the German market with a strategic partnership aiming to catalyze the company’s mission of providing remote-health solutions and analytics-based patient treatments to the world.
Germany’s winning party – the Social Democrats – are currently in talks with the Greens and Free Democratic Party to form a coalition to replace Angela Merkel’s current government. A pre-election analysis by Volt Face revealed that the Social Democrats “can generally be considered pro-cannabis policy reform,” with even greater pro-cannabis sentiment among the other members of the proposed coalition (https://ibn.fm/PpZMv).
Though access to cannabis in Germany may be limited, the current system appears to be serving as a model for the rest of the European Union through policies that demonstrate a controlled, prescribed, and relatively efficient medical cannabis market (https://ibn.fm/kGG8F). Recent reports by the Prohibition Partners organization, based on translated publications from the German Bundestag, provided positive insights into the German medical cannabis model and possible implications for the rest of the European Union.
According to the report, there are slightly more than 13,000 complete patient records from roughly 128,000 patients receiving medical cannabis in the country. Market analysts predict one million medical cannabis patients in Germany by 2024 with a total market value of $8.9 billion by 2028, making it one of “the world’s most valuable medical cannabis markets,” according to the New Frontier Data organization.
“Germany represents one of the most important and influential plant-based medicine markets in Europe, and we are thrilled to be initiating a pilot program with Four 20 Pharma GmbH in the region,” said Gregory Wagner, RYAH Group CEO. “Four 20 has a strong network of doctors and patient care facilities, making it an excellent partner to pilot RYAH’s smart inhaler and proprietary data analytics as the industry moves towards perfecting prescribing practices and patient regimens.”
RYAH provides an ecosystem of IoT products that include volume-control devices, medicine-carrying components, and mobile applications. Used together, they can provide a reliable way for researchers and clinicians to develop well-controlled environments to study the use of cannabis for chronic medical conditions and palliative care. Along with treatment administration, RYAH’s infrastructure aims to generate AI-powered models that can provide precision treatments for various diseases.
RYAH is dedicated to leveraging technological innovation that unlocks the power of data to provide better patient outcomes. The company’s robust intellectual property portfolio, comprised of AI-powered technology and portable, cost-effective products, is positioning the company to capture and capitalize on growth opportunities in Germany, the European Union, and beyond.
For more information, visit the company’s website at www.RYAHGroup.com.
NOTE TO INVESTORS: The latest news and updates relating to RYAH are available in the company’s newsroom at https://ibn.fm/RYAH
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.investorwire.com
InvestorWire is part of the InvestorBrandNetwork.